{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:34:12Z","timestamp":1790508852256,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007921","name":"University of Pittsburgh","doi-asserted-by":"publisher","award":["CCSG P30 CA047904"],"award-info":[{"award-number":["CCSG P30 CA047904"]}],"id":[{"id":"10.13039\/100007921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.10.032","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:56:46Z","timestamp":1762012606000},"page":"173.e1-173.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed\/Refractory Diffuse Large B Cell Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-1834","authenticated-orcid":false,"given":"Ilias","family":"Christodoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"McFarquhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dorritie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren D.","family":"Shlomchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.jtct.2025.10.032_bib0001","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.032_bib0002","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.032_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.032_bib0004","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.032_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.032_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.032_bib0007","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10254","key":"10.1016\/j.jtct.2025.10.032_bib0008","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.032_bib0009","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Advances"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.032_bib0010","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"issue":"2, Supplement","key":"10.1016\/j.jtct.2025.10.032_bib0011","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jtct.2023.12.249","article-title":"Real-world comparison of lisocabtagene maraleucel (Liso-Cel) and axicabtagene ciloleucel (Axi-Cel): efficacy & toxicity","volume":"30","author":"Portuguese","year":"2024","journal-title":"Transplantat Cellul Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.032_bib0012","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.032_bib0013","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.032_bib0014","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Experiment Med"},{"issue":"23","key":"10.1016\/j.jtct.2025.10.032_bib0015","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood.V126.23.3773.3773","article-title":"Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T Cells and clinical outcome in adults with B cell acute lymphoblastic leukemia","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.032_bib0016","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","article-title":"Fludarabine: a review of the clear benefits and potential harms","volume":"37","author":"Lukenbill","year":"2013","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.032_bib0017","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.032_bib0018","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","article-title":"Cyclophosphamide toxicity. Characterising and avoiding the problem","volume":"42","author":"Fraiser","year":"1991","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.032_bib0019","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtct.2022.08.002","article-title":"Perspective: an International fludarabine shortage: supply chain issues impacting transplantation and immune effector cell therapy delivery","volume":"28","author":"Maziarz","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"Pt 2","key":"10.1016\/j.jtct.2025.10.032_bib0020","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.clinthera.2009.11.031","article-title":"Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma","volume":"31","author":"Dennie","year":"2009","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.032_bib0021","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2141.2012.09106.x","article-title":"Gribben JG. T-cell replete fludarabine\/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies","volume":"157","author":"Auer","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.032_bib0022","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.032_bib0023","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","article-title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","volume":"8","author":"Ghilardi","year":"2024","journal-title":"Blood Advances"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.032_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.032_bib0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.032_bib0026","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Advances"},{"issue":"27","key":"10.1016\/j.jtct.2025.10.032_bib0027","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.032_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.jtct.2025.10.032_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.jtct.2025.10.032_bib0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T Outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.032_bib0031","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.10.032_bib0032","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.032_bib0033","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2025.10.032_bib0034","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2025.10.032_bib0035","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.032_bib0036","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtct.2025.03.011","article-title":"Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma","volume":"31","author":"Shouval","year":"2025","journal-title":"Transplant Cellul Ther"},{"issue":"27","key":"10.1016\/j.jtct.2025.10.032_bib0037","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.032_bib0038","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri\u2013CAR-T practice patterns and survival predictors for all CAR-T patients and post\u2013CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.032_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jtct.2025.10.032_bib0040","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma","volume":"98","author":"Ong","year":"2023","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.10.032_bib0041","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200269","article-title":"Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse\/Refractory (r\/r) Large B-Cell Lymphoma (LBCL)","volume":"144","author":"Ali","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.032_bib0042","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-024-01542-9","article-title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","volume":"17","author":"Ghilardi","year":"2024","journal-title":"J Hematol Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:54:25Z","timestamp":1773842065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725015441"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.032","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed\/Refractory Diffuse Large B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}